Disc Medicine, Inc. IRON

Company Overview

Disc Medicine, Inc. (NASDAQ: IRON) is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapies for patients with severe hematologic diseases. The company operates within the biotechnology and pharmaceutical research and development industries, with a specific emphasis on disorders of iron homeostasis and erythropoiesis.

The company’s core value proposition centers on targeting the hepcidin pathway, a key regulator of systemic iron balance. Disc Medicine’s lead programs are aimed at treating rare and serious blood disorders characterized by iron dysregulation, including anemia and iron overload conditions. Founded in 2017 and headquartered in Cambridge, Massachusetts, Disc Medicine has evolved from early translational research into a publicly traded company following its initial public offering in 2021, advancing multiple assets through clinical development.